| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Arginase
|
|---|---|
| ln Vitro |
The arginase inhibitor nor−NOHA induces apoptosis in ARG2 expressing cells.
Nor−NOHA attenuates hypoxia-mediated resistance towards imatinib.
Cell death induced by nor−NOHA is independent of ARG2.
ARG2 knockout and nor−NOHA have distinct effects on cellular respiration.
ARG2−expressing leukemic cells, including CML progenitors, were sensitive to the arginase inhibitor nor−NOHA under hypoxia. As such, nor−NOHA could overcome hypoxia-mediated imatinib resistance in CML progenitors. Unexpectedly, through extensive validation employing RNAi and CRISPR/Cas9 mutagenesis, we found that ARG2 loss-of-function was not responsible for the phenotypes produced by nor−NOHA treatment, although nor−NOHA did inhibit the arginase activity of ARG2.[1]
|
| ln Vivo |
nor-NOHA (100 mg/kg, intravenous injection, once) can significantly reduce infarct size in male Sprague-Dawley rats [2]. nor-NOHA (100 mg/kg IV once) increases plasma citrulline and nitrite levels and decreases plasma ornithine levels in male Sprague-Dawley rats [2]
|
| Enzyme Assay |
Arginase activity assay[1]
Arginase activity was analysed as described with modifications. Cells were counted, and equal numbers of cells were lysed in 50μl of lysis buffer (PBS with 1mM EDTA, 0.1% Triton X−100 and protease Inhibitors) and centrifuged for 15 minutes at 14,000g at 4°C. The supernatants were mixed with 50μl of freshly prepared activation buffer (10mM MnCl2, 50mM Tris-HCl pH7.5) and 50μl of 0.5M arginine, and heated for 10 minutes at 56°C. Thereafter, 800μl of acidic solution (H2SO4 (96%)/H3PO4 (85%)/H2O, 1/3/7, v/v/v) and 25μl of 9% α–isonitrosopropiophenone (in ethanol) were added to the mixture and heated for 15 minutes at 100°C. The mixture was allowed to develop colour in the dark. Finally, 250μl was transferred to a 96-well plate for OD measurements at 550nm. |
| Cell Assay |
Measurement of cellular respiration by Seahorse Analyzer[1]
0.1x106 K562 cells were plated per well in poly–L–lysine-coated XF–24 well cell culture microplates in XF Assay media supplemented with 4.5 g/L glucose and 1mM sodium pyruvate. The cells were spin–immobilized to the microplates at 200g for 1 minute. The cellular oxygen consumption rate (OCR), extracellular acidification rate (ECAR), and photon production rate (PPR) were obtained using an XF24 Analyzer from Seahorse Bioscience. The measurements were performed according to the manufacturer’s instructions, using Oligomycin, Carbonyl cyanide–4–(trifluoromethoxy) phenylhydrazone (FCCP) and Rotenone & antimycin A (R/A; all from Sigma−Aldrich) at the specified concentrations. Data was analysed using the Seahorse XF software. |
| Animal Protocol |
Sprague-Dawley rats were subjected to 30 min of coronary artery ligation, followed by 2 h of reperfusion. The animals were given either saline, or the arginase inhibitor N-omega-hydroxy-nor-l-arginine (nor-NOHA) with or without the NO scavenger carboxy-2-phenyl-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide (cPTIO) or the NOS inhibitor N(G)-monomethyl-l-arginine (l-NMMA) iv 15 min before ischaemia. The infarct size was 79 +/- 4% of the area at risk in the control group. Nor-NOHA treatment reduced the infarct size to 39 +/- 7% (P < 0.001). Administration of cPTIO or l-NMMA completely abolished the protective effect of nor-NOHA. Expression of arginase I was significantly (P < 0.05) increased in ischaemic myocardium. Nor-NOHA treatment resulted in higher plasma levels of nitrite (P < 0.05) and a 10-fold increase in the citrulline/ornithine ratio (P < 0.001), indicating a shift in arginine utilization towards NOS.
Conclusion: Inhibition of arginase protects from myocardial infarction by a mechanism that is dependent on NOS activity and bioavailability of NO by shifting arginine utilization from arginase towards NOS. These findings suggest that targeting of arginase is a promising future therapeutic strategy for protection against myocardial IR injury.[2] |
| References |
|
| Additional Infomation |
Nomega-hydroxy-nor-l-arginine is a L-alpha-amino acid.
N-Hydroxy-nor-L-arginine (nor-NOHA) is under investigation in clinical trial NCT02009527 (Arginase Inhibition in Ischemia-reperfusion Injury). |
| Molecular Formula |
C5H14CL2N4O3
|
|---|---|
| Molecular Weight |
249.092
|
| Exact Mass |
176.091
|
| Elemental Analysis |
C, 24.11; H, 5.67; Cl, 28.46; N, 22.49; O, 19.27
|
| CAS # |
291758-32-2
|
| Related CAS # |
189302-40-7; 1140844-63-8 (acetate); 291758-32-2 (HCl); 2250019-93-1 (nor-NOHA monoacetate)
|
| PubChem CID |
446124
|
| Appearance |
Colorless to light yellow solid powder
|
| LogP |
-4.6
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
12
|
| Complexity |
182
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
ON/C(=N/CC[C@@H](C(=O)O)N)/N
|
| InChi Key |
AKPIIXWPTMFQQJ-QTNFYWBSSA-N
|
| InChi Code |
InChI=1S/C5H12N4O3.2ClH/c6-3(4(10)11)1-2-8-5(7)9-12;;/h3,12H,1-2,6H2,(H,10,11)(H3,7,8,9);2*1H/t3-;;/m0../s1
|
| Chemical Name |
(S,E)-2-amino-4-(2-hydroxyguanidino)butanoic acid dihydrochloride
|
| Synonyms |
N-Hydroxy-nor-L-Arginine; H-norArg(delta-OH)-OH; 189302-40-7; 291758-32-2; Nomega-hydroxy-nor-L-arginine; N-Hydroxy-nor-arginine; N-Hydroxy-nor-L-arginine; (2S)-2-amino-4-[[amino-(hydroxyamino)methylidene]amino]butanoic acid; NOR-N-OMEGA-HYDROXY-L-ARGININE; nor-NOHA HCl; nor-NOHA hydrochloride.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0146 mL | 20.0731 mL | 40.1461 mL | |
| 5 mM | 0.8029 mL | 4.0146 mL | 8.0292 mL | |
| 10 mM | 0.4015 mL | 2.0073 mL | 4.0146 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
